New Dual-Action antibody targets tumors in early trial
NCT ID NCT07266428
First seen Dec 11, 2025 · Last updated May 25, 2026 · Updated 17 times
Summary
This study tests an experimental drug called OTP-01 in about 170 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to attack cancer in two ways—by blocking PD-1 and VEGFR2—to shrink tumors and slow disease. The main goals are to find the safest dose, check for side effects, and see if tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Auckland City Hospital
RECRUITINGAuckland, 1023, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cancer Research SA
RECRUITINGAdelaide, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chris O'Brien Lifehouse
RECRUITINGCamperdown, 2050, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Linear Clinical Research
RECRUITINGNedlands, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
START Dublin Early Phase Clinical Trials Unit
RECRUITINGDublin, D07 R2WY, Ireland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
South Texas Accelerated Research Therapeutics (START)
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
South Texas Accelerated Research Therapeutics (START) Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.